PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival

作者：Ourania Parra, Weijie Ma, Zhongze Li, Bryan N. Coffing, Konstantinos Linos, Robert E. LeBlanc, Shabnam Momtahen, Aravindhan Sriharan, Jeffrey M. Cloutier, Wendy A. Wells, Shaofeng Yan · 发表于：Journal of Cutaneous Pathology · 年份：2023 · DOI：10.1111/cup.14495 · 被引用次数：19 · 研究领域：Cutaneous Melanoma Detection and Management、Immunotherapy and Immune Responses、Melanoma and MAPK Pathways

BACKGROUND: Immunohistochemistry-based protein biomarkers can provide useful prognostic information in cutaneous melanoma. The independent prognostic value of Ki-67 has been studied with variable results. PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemistry is a useful new ancillary tool for distinguishing cutaneous nevi from melanoma; however, its prognostic value has not been well studied. We evaluated PRAME as a prognostic marker in cutaneous melanoma, compared to Ki-67. METHODS: We analyzed the immunohistochemical expression of PRAME and Ki-67 in 165 melanocytic lesions, including 92 primary melanomas, 19 metastatic melanomas, and 54 melanocytic nevi using tissue microarrays. PRAME immunostaining was scored based on the percentage of positive nuclei: 0 <1%, 1+ 1%-25%, 2+ 26%-50%, 3+ 51%-75%, and 4+ >75%. The percentage of Ki-67-positive tumor nuclei was used to calculate the proliferation index. RESULTS: PRAME and Ki-67 both showed significantly increased expression in melanomas compared to nevi (p < 0.0001 and p < 0.001, respectively). There was no significant difference in PRAME expression in primary versus metastatic melanomas. By contrast, the Ki-67 proliferation index was higher in metastatic melanoma than in primary melanoma (p = 0.013). Increased Ki-67 index correlated with ulceration (p < 0.001), increased Breslow depth (p = 0.001), and higher mitotic rate (p < 0.0001), whereas increased PRAME expression correlated with higher mitotic rate (p ...